JP2013530965A - 増殖性疾患の治療 - Google Patents

増殖性疾患の治療 Download PDF

Info

Publication number
JP2013530965A
JP2013530965A JP2013515634A JP2013515634A JP2013530965A JP 2013530965 A JP2013530965 A JP 2013530965A JP 2013515634 A JP2013515634 A JP 2013515634A JP 2013515634 A JP2013515634 A JP 2013515634A JP 2013530965 A JP2013530965 A JP 2013530965A
Authority
JP
Japan
Prior art keywords
seq
cancer
nad1
nucleic acid
plant defensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013515634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013530965A5 (enExample
Inventor
ダレン ハレット，マーク
ホ プーン，アイヴァン，カ
アン アンダーソン，マリリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexima Ltd
Original Assignee
Hexima Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexima Ltd filed Critical Hexima Ltd
Publication of JP2013530965A publication Critical patent/JP2013530965A/ja
Publication of JP2013530965A5 publication Critical patent/JP2013530965A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
JP2013515634A 2010-06-24 2011-06-23 増殖性疾患の治療 Pending JP2013530965A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35812610P 2010-06-24 2010-06-24
US61/358,126 2010-06-24
PCT/AU2011/000760 WO2011160174A1 (en) 2010-06-24 2011-06-23 Treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
JP2013530965A true JP2013530965A (ja) 2013-08-01
JP2013530965A5 JP2013530965A5 (enExample) 2013-10-10

Family

ID=45370753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013515634A Pending JP2013530965A (ja) 2010-06-24 2011-06-23 増殖性疾患の治療

Country Status (12)

Country Link
US (1) US20120172313A1 (enExample)
EP (1) EP2585095A4 (enExample)
JP (1) JP2013530965A (enExample)
KR (1) KR20140003316A (enExample)
CN (1) CN103037888A (enExample)
AU (1) AU2011269726B2 (enExample)
CA (1) CA2803027A1 (enExample)
MX (1) MX2012014711A (enExample)
NZ (1) NZ603442A (enExample)
SG (1) SG186385A1 (enExample)
WO (1) WO2011160174A1 (enExample)
ZA (1) ZA201208389B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520121A (ja) * 2015-05-29 2018-07-26 ヘキシマ リミテッドＨｅｘｉｍａ Ｌｉｍｉｔｅｄ インビボ治療の方法
KR102371762B1 (ko) * 2020-12-29 2022-03-07 중앙대학교 산학협력단 Brca1 매개 nsd2 유비퀴틴화를 통한 세포 분화 및 세포사멸 조절 용도

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2673365B1 (en) 2011-02-07 2017-12-20 Hexima Limited Modified plant defensins useful as anti-pathogenic agents
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013039861A2 (en) * 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
EP2768849B1 (en) 2011-10-19 2017-09-27 Hexima Limited Novel plant defensins and use in the treatment of proliferative diseases
CN111751345A (zh) * 2020-07-08 2020-10-09 深圳海关动植物检验检疫技术中心 一种苜蓿黄萎病菌活性检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002063011A1 (en) * 2001-02-08 2002-08-15 Hexima Ltd Plant-derived molecules and genetic sequences encoding same and uses therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016423A2 (en) * 2000-08-25 2002-02-28 Basf Plant Science Gmbh PLANT POLYNUCLEOTIDES ENCODING NOVEL Na+/H+ ANTIPORTERS
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
CN104522032B (zh) * 2008-08-05 2017-01-18 赫希玛有限公司 植物抗病原体系统

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002063011A1 (en) * 2001-02-08 2002-08-15 Hexima Ltd Plant-derived molecules and genetic sequences encoding same and uses therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6015019746; Ｃａｒｖａｌｈｏ，　Ａｄｅ．　Ｏ１．　ｅｔ　ａｌ．，　Ｐｅｐｔｉｄｅｓ，　２００９，　ｖｏｌ．３０，　ｎｏ．５，　ｐ．１００７-２０ *
JPN6015019747; Ａｎａｙａ-Ｌｏ'ｐｅｚ，　Ｊ．　Ｌ．　ｅｔ　ａｌ．，　Ｂｉｏｔｅｃｈｎｏｌ．　Ｌｅｔｔ．，　２００６，　ｖｏｌ．２８，　ｎｏ．１４，　ｐ．１１０１-８ *
JPN6015019748; Ｌａｙ，　Ｆ．　Ｔ．，　ｅｔ　ａｌ．，　Ｃｕｒｒ．　Ｐｒｏｔｅｉｎ．　Ｐｅｐｔ．　Ｓｃｉ．，　２００５，　ｖｏｌ．６，　ｎｏ．１，　ｐ．８５-１０１ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520121A (ja) * 2015-05-29 2018-07-26 ヘキシマ リミテッドＨｅｘｉｍａ Ｌｉｍｉｔｅｄ インビボ治療の方法
KR102371762B1 (ko) * 2020-12-29 2022-03-07 중앙대학교 산학협력단 Brca1 매개 nsd2 유비퀴틴화를 통한 세포 분화 및 세포사멸 조절 용도

Also Published As

Publication number Publication date
CA2803027A1 (en) 2011-12-29
US20120172313A1 (en) 2012-07-05
WO2011160174A1 (en) 2011-12-29
NZ603442A (en) 2013-09-27
ZA201208389B (en) 2013-06-26
EP2585095A4 (en) 2013-11-13
SG186385A1 (en) 2013-01-30
AU2011269726A1 (en) 2012-11-29
KR20140003316A (ko) 2014-01-09
AU2011269726B2 (en) 2013-11-28
CN103037888A (zh) 2013-04-10
EP2585095A1 (en) 2013-05-01
MX2012014711A (es) 2013-03-21

Similar Documents

Publication Publication Date Title
Kim et al. In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines
Nair et al. Antimicrobial activity of omwaprin, a new member of the waprin family of snake venom proteins
Silva et al. Defensins: antifungal lessons from eukaryotes
JP2013530965A (ja) 増殖性疾患の治療
Cools et al. Antifungal plant defensins: increased insight in their mode of action as a basis for their use to combat fungal infections
Taveira et al. Thionin‐like peptides from Capsicum annuum fruits with high activity against human pathogenic bacteria and yeasts
Petersen et al. Peanut defensins: Novel allergens isolated from lipophilic peanut extract
TWI655906B (zh) 使用台灣假單孢菌（Ｐｓｅｕｄｏｍｏｎａｓ ｔａｉｗａｎｅｎｓｉｓ）控制昆蟲及微生物之組合物及方法
Ravipati et al. Lysine-rich cyclotides: A new subclass of circular knotted proteins from violaceae
Xue et al. Chlamydomonas reinhardtii-expressed multimer of ToAMP4 inhibits the growth of bacteria of both Gram-positive and Gram-negative
Palavalli et al. Imbibition of soybean seeds in warm water results in the release of copious amounts of Bowman–Birk protease inhibitor, a putative anticarcinogenic agent
Mangoni et al. Functional characterisation of the 1–18 fragment of esculentin-1b, an antimicrobial peptide from Rana esculenta
Zhang et al. Secretion expression of human neutrophil peptide 1 (HNP1) in Pichia pastoris and its functional analysis against antibiotic-resistant Helicobacter pylori
El-Defrawy et al. G-protein-coupled receptors in fungi
US9540423B2 (en) Plant defensins and use in the treatment of proliferative diseases
Riciluca et al. Rondonin: antimicrobial properties and mechanism of action
Li et al. Modes of action and potential as a peptide‐based biofungicide of a plant defensin MtDef4
Barragán-Cárdenas et al. Changes in length and positive charge of palindromic sequence RWQWRWQWR enhance cytotoxic activity against breast cancer cell lines
Yap et al. Expansion of Hydra actinoporin-like toxin (HALT) gene family: Expression divergence and functional convergence evolved through gene duplication
Lopes et al. Interaction of antimicrobial peptide Plantaricin149a and four analogs with lipid bilayers and bacterial membranes
Khan et al. Antimicrobial plant peptides: structure, classification, mechanism and therapeutic potential
TWI634210B (zh) 抑制熱休克蛋白質表現之胜肽及包含其之組成物
Barkhuizen Mode of action studies of defensin peptides from native South African Brassicaceae species
Landi et al. Effects of indicitin, a novel ribosome-targeting enzyme from milky mushrooms, on four human cell lines and the gut microbiota
AL SOUHAIL Characterization, regulation and biophysical studies of immune-related peptides from Manduca sexta

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130822

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20131010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150526

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151027